N-(3,5-Bis-trifluoromethyl-benzyl)-5-[2,4-dioxo-thiazolidin-(5E)-ylidenemethyl]-2-methoxy-benzamide | 185808-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,5-Bis-trifluoromethyl-benzyl)-5-[2,4-dioxo-thiazolidin-(5E)-ylidenemethyl]-2-methoxy-benzamide
• CAS: 185808-44-0
• 化学式: C₂₁H₁₄F₆N₂O₄S
• 分子量: 504.41
• InChiKey: SPNYYQYNKQXHMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.99
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  84.5
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-(3,5-Bis-trifluoromethyl-benzyl)-5-[2,4-dioxo-thiazolidin-(5E)-ylidenemethyl]-2-methoxy-benzamide 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 N-(3,5-Bis-trifluoromethyl-benzyl)-5-(2,4-dioxo-thiazolidin-5-ylmethyl)-2-methoxy-benzamide
  参考文献：
  名称：

  (3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

  摘要：

  A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl] -2-methoxy-N-[[4-trifluoromethyl)phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00039-6
• 作为产物：
  描述：

  5-[2,4-Dioxo-thiazolidin-(5E)-ylidenemethyl]-2-methoxy-benzoic acid methyl ester 在 盐酸 、 氰基磷酸二乙酯 、 三乙胺 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,5-Bis-trifluoromethyl-benzyl)-5-[2,4-dioxo-thiazolidin-(5E)-ylidenemethyl]-2-methoxy-benzamide
  参考文献：
  名称：

  (3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

  摘要：

  A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl] -2-methoxy-N-[[4-trifluoromethyl)phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00039-6